Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Q1 2022 vs. Q4 2021
How the institutions holding Cingulate Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 5 | 6 | +1 |
| Shares | 1.11M | 1.08M | −29.2K (−2.6%) |
| Value | $3.06M | $2.13M | −$936.0K (−30.5%) |
New holders (4)
Institutions that held Cingulate Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 51,000 | $100.0K | 0.00% |
| Eagle Asset Management Inc | 47,895 | $94.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,961 | $4.00K | 0.00% |
| Wells Fargo & Company | 26 | $0 | 0.00% |
Sold out (3)
Institutions that held Cingulate Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Altium Capital Management LP | 83,931 | $232.0K |
| Susquehanna International Group, LLP | 10,338 | $29.0K |
| UBS Group AG | 4,716 | $13.0K |